Fosbøl E L, Gislason G H, Jacobsen S, Folke F, Hansen M L, Schramm T K, Sørensen R, Rasmussen J N, Andersen S S, Abildstrom S Z, Traerup J, Poulsen H E, Rasmussen S, Køber L, Torp-Pedersen C
Department of Cardiology, Gentofte University Hospital, Hellerup, Denmark.
Clin Pharmacol Ther. 2009 Feb;85(2):190-7. doi: 10.1038/clpt.2008.204. Epub 2008 Nov 5.
Use of some nonsteroidal anti-inflammatory drugs (NSAIDs) is associated with increased cardiovascular risk in several patient groups, but whether this excess risk exists in apparently healthy individuals has not been clarified. Using a historical cohort design, we estimated the risk of death and myocardial infarction associated with the use of NSAIDs. Participants in the study were selected from the Danish population and were defined as healthy according to a history of no hospital admissions and no concomitant selected pharmacotherapy. The source population consisted of 4,614,807 individuals, of whom 1,028,437 were included in the study after applying selection criteria. Compared to no NSAID use, hazard ratios (95% confidence limits) for death/myocardial infarction were 1.01 (0.96-1.07) for ibuprofen, 1.63 (1.52-1.76) for diclofenac, 0.97 (0.83-1.12) for naproxen, 2.13 (1.89-2.41) for rofecoxib, and 2.01 (1.78-2.27) for celecoxib. A dose-dependent increase in cardiovascular risk was seen for selective COX-2 inhibitors and diclofenac. Caution should be exercised in NSAID use in all individuals, and particularly high doses should be avoided if possible.
在一些患者群体中,使用某些非甾体抗炎药(NSAIDs)与心血管风险增加相关,但在看似健康的个体中是否存在这种额外风险尚未明确。我们采用历史性队列设计,估计了使用NSAIDs相关的死亡和心肌梗死风险。研究参与者从丹麦人群中选取,根据无住院史和无伴随特定药物治疗史被定义为健康个体。源人群包括4,614,807人,应用选择标准后,其中1,028,437人被纳入研究。与未使用NSAIDs相比,布洛芬导致死亡/心肌梗死的风险比(95%置信区间)为1.01(0.96 - 1.07),双氯芬酸为1.63(1.52 - 1.76),萘普生为0.97(0.83 - 1.12),罗非昔布为2.13(1.89 - 2.41),塞来昔布为2.01(1.78 - 2.27)。选择性COX - 2抑制剂和双氯芬酸的心血管风险呈剂量依赖性增加。所有个体使用NSAIDs时都应谨慎,如有可能应特别避免高剂量使用。